A. Hasselberg

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis

C. Calonder, R. Woessner, R. Soon, 2019, Clinical pharmacology and therapeutics.

IL-17A inhibition by secukinumab induces early clinical, histopathological, and molecular resolution of psoriasis.

Xiaoyu Jiang, R. Hillenbrand, W. Hueber, 2019, The Journal of allergy and clinical immunology.

OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary sjÖgren’s syndrome

T. Dörner, M. Cabański, M. Zeher, 2018, FRIDAY, 15 JUNE 2018.

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

B. Sloth, A. Šedivá, L. Folio, 2018, Blood.